Dihexa (10mg)
Dihexa (N-hexanoic-Tyr-Ile-(6)aminohexanoic amide) is a potent nootropic peptide derived from Angiotensin IV, ~10 million times more potent than BDNF at synaptogenesis. It is administered sublingually, per os, or subcutaneously. ⚠️ Dihexa is not water-soluble—it requires DMSO or PG as a solvent.
Reviewed by the AllPeptides.eu Editorial Team·Last reviewed: 2026-06-16
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
⚠️ For informational/educational purposes only. Not medical advice. We do not sell any products. Self-treatment carries serious risks — consult a healthcare professional. Disclaimer
How It Works
Dihexa enhances HGF/c-Met signaling, promoting the formation of new synapses (synaptogenesis), neurogenesis, and memory improvement in models of cognitive decline.
Quick Start
- Reconstitution (Injectable): Dissolve in 1.0 mL DMSO → 10 mg/mL. ⚠️ NO BAC water—Dihexa does not dissolve in water.
- Typical Dose (SubQ): 0.5–2 mg subcutaneously, 1×/day.
- Per os / Sublingual: 5–20 mg daily (lower bioavailability).
- Storage: Powder: −20 °C; DMSO solution: 2–8 °C, use within 21 days.
Dosing Table — Dihexa 10mg
Route: Subcutaneous (DMSO) or Sublingual | Frequency: 1× daily
| Week | Dose | Units (per injection) |
|---|---|---|
| Wk. 1 (SubQ) | 0.5 mg | 5 Units (0.05 mL) |
| Wk. 2–4 (SubQ) | 1 mg | 10 Units (0.10 mL) |
| Wk. 5+ (SubQ) | 2 mg | 20 Units (0.20 mL) |
| Per os alternative | 5–20 mg | 50–200 Units (0.50–2.00 mL) |
Injectable (SubQ): Lower doses due to high bioavailability (0.5–2 mg). Per os/sublingual: 5–20 mg due to low absorption. Cycle for 4–8 weeks. Research peptide—limited data.
Related compounds
Reconstitution Steps
- ⚠️ Dihexa is not water-soluble. DO NOT use bacteriostatic water.
- For injection (SubQ): Dissolve in 1.0 mL DMSO (dimethyl sulfoxide) → 10 mg/mL.
- For sublingual use: Dissolve in DMSO or PG (propylene glycol) under guidance.
- Slowly inject the solvent; gently swirl until fully dissolved.
- Store at 2–8 °C, protected from light. Use within 21 days.
Protocol Overview
- Dihexa (N-hexanoic-Tyr-Ile-(6)aminohexanoic amide) is an Angiotensin IV derivative.
- Activates the HGF/c-Met receptor, critical for synaptogenesis.
- Extremely potent—active at nanomolar concentrations.
- Available as a SubQ injection (in DMSO) or per os/sublingual (capsules).
Dosing Protocol
- SubQ (injectable): Start with 0.5 mg/day, increase to 1–2 mg.
- Per os: 5–20 mg/day sublingually or in capsules.
- Cycle: 4–8 weeks on, 4 weeks off.
- Investigational—for use under medical guidance only.
- Break between cycles: After the cycle (4–8 weeks), a washout period of 4–6 weeks is recommended. Dihexa enhances HGF/c-Met—the break prevents overstimulation.
Washout & Cycle Restart
When can I restart?
After the cycle (4–8 weeks), a washout period of 4–6 weeks is recommended. Dihexa enhances HGF/c-Met—the break prevents overstimulation.
Minimum wait period: 4 weeks
Storage Instructions
- Powder: −20 °C, away from light.
- DMSO solution: 2–8 °C, use within 21 days.
Important Notes
- Investigational peptide—limited clinical data.
- NOT water-soluble—use only DMSO or PG.
- Potential effect on angiogenesis—avoid with a history of cancer.
- Medical supervision is required.
Potential Benefits & Side Effects
Potential Benefits:
- Potent synaptogenesis
- Improved memory and learning
- Neuroprotective action
- Potential restoration of cognitive decline
- Enhanced HGF/c-Met signaling
Potential Side Effects:
- Headache (rare)
- Mild stinging at injection site (due to DMSO)
- Potential angiogenesis (theoretical concern)
- Limited safety data
⚠️ Serious Warnings & Long-Term Risks
The following warnings are based on published literature, FDA labels, and post-marketing surveillance. They do not constitute medical advice. Consult a healthcare professional.
Potent angiogenesis & potential oncogenesis
Dihexa is 10⁷× more potent than BDNF at c-Met/HGF binding. The c-Met receptor is a known oncogene — overexpressed in many cancers. No safety profile in humans.
📄 J Pharmacol Exp Ther 2013Unclear neurotoxicity
As an extremely potent c-Met agonist without human trials, neurotoxicity cannot be excluded. Excessive neural growth may be pathological.
📄 J Pharmacol Exp Ther 2013References
- Dihexa Synaptogenesis — McCoy AT, et al. A novel HGF/c-Met-enhancing peptide promotes cognitive restoration. J Pharmacol Exp Ther. 2013;344(2):431-440.
View Source - Dihexa Cognitive Restoration — Chai SY, et al. AngIV-analog Dihexa rescues cognitive impairment and recovers memory in the APP/PS1 mouse via the PI3K/AKT signaling pathway. Brain Sci. 2021;11(11):1459.
View Source
Recommended Supplements
Omega-3 DHA
Lion's Mane (Hericium erinaceus)
Phosphatidylserine
External Sources & Regulatory Status
Regulatory Approvals
Research-only — HGF/c-Met agonist (preclinical)
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
Continue Your Research
Explore tools and guides related to this protocol.
Important Disclaimer
The content of this website is provided exclusively for informational and educational purposes within the context of research literature.
Read the full Disclaimer →